Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70.

IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026. "Alexander disease is a devastating condition,.

Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglycerides and 85% reduction in acute pancreatitis events, with no comparable competition in efficacy. Current guidance assumes reaching only 10% of the 1M high-risk U.S. sHTG patients, with pricing likely near $20,000 per patient annually.

Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript